Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03685344 | Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma | terminated | Phase 1 | 13 | ADC Therapeutics S.A.INDUSTRY | 2 | Oct 26, 2021 | clinicaltrials |
| NCT00256776 | MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation | terminated | Phase 3 | 269 | European Society for Blood and Marrow TransplantationNETWORK | 10 | Oct 18, 2021 |
| clinicaltrials |
| NCT03537222 | Quality of Life in Patients With Multiple Myeloma-validation Study | terminated | — | 58 | Zurich University of Applied SciencesOTHER | 1 | Oct 14, 2021 | clinicaltrials |
| NCT02840110 | Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product | terminated | — | 22 | Cogent Biosciences, Inc.INDUSTRY | 1 | Oct 11, 2021 | clinicaltrials |
| NCT01585688 | Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL | terminated | Phase 1 / Phase 2 | 13 | Gilead SciencesINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT02576977 | Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) | terminated | Phase 3 | 251 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 8, 2021 | clinicaltrials |
| NCT01549886 | Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 5 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Oct 4, 2021 | clinicaltrials |
| NCT01662102 | Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) | terminated | Phase 3 | 1 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Oct 4, 2021 | clinicaltrials |
| NCT03403725 | MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study(CD205SHUTTLE) | terminated | Phase 1 | 28 | Menarini GroupINDUSTRY | 4 | Sep 28, 2021 | clinicaltrials |
| NCT03585725 | A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma | terminated | Early Phase 1 | 3 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT02394210 | Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma(EPA-MMBR) | terminated | — | 415 | CelgeneINDUSTRY | 1 | Sep 14, 2021 | clinicaltrials |
| NCT01045382 | MSC and HSC Coinfusion in Mismatched Minitransplants | terminated | Phase 2 | 39 | University of LiegeOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT00113802 | Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia | terminated | Phase 2 | 31 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT01663766 | Phase I Study of Milatuzumab for Graft Versus Host Disease | terminated | Phase 1 | 12 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT01728207 | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | terminated | Phase 1 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT00490776 | Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL) | terminated | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 18, 2021 | clinicaltrials |
| NCT00054834 | Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma | terminated | Phase 1 | 27 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT01101594 | A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 17 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT02489123 | Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | terminated | Phase 2 | 8 | University of WashingtonOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT03618212 | MRI in Multiple Myeloma: Analysis of the Axial Skeleton Versus Whole Body. What is the Required Analysis?(MYMO) | terminated | — | 12 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT04730505 | A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM(MyHOPE™) | terminated | Phase 1 | 2 | CelgeneINDUSTRY | 1 | Aug 9, 2021 | clinicaltrials |
| NCT03634800 | Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)(RISE-M) | terminated | Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT01946152 | Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT03892525 | Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma | terminated | Phase 1 | 4 | The Lymphoma Academic Research OrganisationOTHER | 1 | Jul 26, 2021 | clinicaltrials |
| NCT04178902 | A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma | terminated | Phase 1 | 8 | AbbVieINDUSTRY | 7 | Jul 26, 2021 | clinicaltrials |
| NCT01434472 | High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma | terminated | Phase 2 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT02579863 | Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185) | terminated | Phase 3 | 310 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 20, 2021 | clinicaltrials |
| NCT02867618 | Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma | terminated | Phase 1 / Phase 2 | 14 | Columbia UniversityOTHER | 1 | Jul 16, 2021 | clinicaltrials |
| NCT03178201 | TGR1202 in Relapsed and Refractory Follicular Lymphoma | terminated | Phase 2 | 5 | Columbia UniversityOTHER | 1 | Jul 16, 2021 | clinicaltrials |
| NCT00445068 | Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma | terminated | Phase 2 | 38 | Novartis PharmaceuticalsINDUSTRY | 2 | Jul 14, 2021 | clinicaltrials |
| NCT02928510 | Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma | terminated | — | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 14, 2021 | clinicaltrials |
| NCT03567616 | A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 8 | AbbVieINDUSTRY | 3 | Jun 30, 2021 | clinicaltrials |
| NCT02128230 | UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | terminated | Phase 2 | 20 | University of ArkansasOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT02323230 | A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL | terminated | Phase 2 | 4 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 1 | Jun 22, 2021 | clinicaltrials |
| NCT02757326 | ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma(ABC-103) | terminated | Phase 1 / Phase 2 | 13 | RedHill Biopharma LimitedINDUSTRY | 1 | Jun 18, 2021 | clinicaltrials |
| NCT03687125 | Tinostamustine Conditioning and Autologous Stem Cell(TITANIUM1) | terminated | Phase 1 / Phase 2 | 6 | Mundipharma-EDO GmbHINDUSTRY | 3 | Jun 18, 2021 | clinicaltrials |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | terminated | Phase 2 / Phase 3 | 40 | Kiadis PharmaINDUSTRY | 7 | Jun 14, 2021 | clinicaltrials |
| NCT03520985 | Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma(OptiPOM) | terminated | Phase 2 | 34 | Swiss Cancer InstituteOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT00003511 | Antineoplaston Therapy in Treating Patients With Multiple Myeloma | terminated | Phase 2 | 5 | Burzynski Research InstituteOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT03065790 | Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide | terminated | — | 1 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT03579888 | CD19-Specific T Cells Post AlloSCT | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT01644253 | Phase 1b Safety and Efficacy Study of TRU-016 | terminated | Phase 1 | 87 | Aptevo TherapeuticsINDUSTRY | 1 | May 20, 2021 | clinicaltrials |
| NCT03910439 | Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | May 12, 2021 | clinicaltrials |
| NCT03154710 | Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response | terminated | N/A | 52 | WepromOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT01999335 | A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 | 33 | AmgenINDUSTRY | 1 | Apr 27, 2021 | clinicaltrials |
| NCT02341209 | Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma(CTCL) | terminated | Phase 2 | 1 | Rochester General HospitalOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT01125293 | Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | terminated | Phase 1 / Phase 2 | 46 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2021 | clinicaltrials |
| NCT01079429 | Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.(GENOMGUS) | terminated | — | 1,200 | Rennes University HospitalOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT02036502 | A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023) | terminated | Phase 1 | 77 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 8, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Oct 26, 2021source: clinicaltrials